Viking Therapeutics (VKTX) Net Cash Flow (2014 - 2026)

Viking Therapeutics has reported Net Cash Flow for 13 years, with the latest figure at $7.8 million in Q2 2026.

• Quarterly Net Cash Flow rose 293.8% year-over-year to $7.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $92.1 million (up 1027.95% YoY) and the FY2025 annual result came in at $139.1 million, up 584.95% from the prior year.
• Net Cash Flow advanced to $7.8 million in Q2 2026 per VKTX's latest filing, from -$47.7 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $140.1 million in Q1 2024 and troughed at -$151.7 million in Q2 2024.
• A 5-year average of $5.6 million and a median of $6.8 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2023 and 2026: Net Cash Flow jumped 1195.85% in 2023, then slumped 523.6% in 2026.
• Over 5 years, Net Cash Flow stood at $7.1 million in 2022, then surged by 158.1% to $18.3 million in 2023, then slumped by 229.08% to -$23.6 million in 2024, then soared by 377.26% to $65.4 million in 2025, then tumbled by 88.01% to $7.8 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $7.8 million, -$47.7 million, and $65.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.